Skip to main content

Table 3 Endoscopic finding of the two studied groups

From: Survival benefits of adding simvastatin to standard therapy for secondary prevention of bleeding esophageal varices in patients with hepatitis C-related liver cirrhosis

Endoscope

Group I

Group II

X2

p-value

15 days

Grade 2

N

21

24

2.237

0.327

%

52.5%

60.0%

Grade 3

N

13

14

%

32.5%

35.0%

Grade 4

N

6

2

%

15.0%

5.0%

3 months

Grade 2

N

22

31

5.901

0.052

%

55.0%

77.5%

Grade 3

N

12

8

%

30.0%

20.0%

Grade 4

N

6

1

%

15.0%

2.5%

6 months

Grade 2

N

27

33

5.667

0.059

%

67.5%

82.5%

Grade 3

N

8

7

%

20.0%

17.5%

Grade 4

N

5

0

%

12.5%

.0%

9 months

Grade 2

N

32

35

3.134

0.209

%

80.0%

87.5%

Grade 3

N

5

5

%

12.5%

12.5%

Grade 4

N

3

0

%

7.5%

.0%

12 months

Grade 2

N

32

35

3.134

0.209

%

80.0%

87.5%

Grade 3

N

5

5

%

12.5%

12.5%

Grade 4

N

3

0

%

7.5%

0%